A study links long-term PM2.5 air pollution to higher levels of anti-nuclear antibodies, early warning signs of autoimmune ...
Thermo Fisher expands its Gibco Bacto CD portfolio with new formulations aimed at boosting E. coli-based plasmid DNA and protein production efficiency.
Thermo Fisher Scientific (NYSE: TMO) has outperformed the market over the past 15 years by 4.96% on an annualized basis producing an average annual return of 16.87%. Currently, Thermo Fisher ...
For patients with food allergies and their families, shopping is not the only thing stressing them out during the holiday ...
Fintel reports that on December 15, 2025, Wells Fargo maintained coverage of Thermo Fisher Scientific (NYSE:TMO) with a ...
Thermo Fisher Scientific Inc. has introduced Gibco Bacto CD Supreme FPM Plus and Gibco Bacto CD Supreme Feed (2X).
The new Gibco™ Bacto™ CD Supreme FPM Plus and Feed (2X) address these needs by simplifying E. coli bioprocessing workflows and delivering predictable, high-quality results. Engineered to deliver ...
According to Mordor Intelligence, the healthcare IT market is valued at USD 413.14 billion in 2025, and is projected to surpass USD 839.67 billion by 2030, at a CAGR of 15.24% during the forecast ...
According to The Fly, on December 2, 2025, Morgan Stanley analyst Kallum Titchmarsh established a price objective of $670, up from $656. He initiated coverage of Thermo Fisher Scientific Inc.
According to editorialists, the study has the potential for major clinical impact, but more work is needed before guidelines ...
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $390.0 to $560.0 for Thermo Fisher Scientific over the recent three months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback